Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
Sign Up to like & getrecommendations! Published in 2019 at "Dermatology and Therapy"
DOI: 10.1007/s13555-019-00337-y
Abstract: Introduction Rapid improvement of psoriasis is valued by patients and should be considered to be an important factor in treatment selection. We investigated Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI)… read more here.
Keywords: rapid response; dermatology; psoriasis; moderate severe ... See more keywords
Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
Sign Up to like & getrecommendations! Published in 2020 at "Dermatology and Therapy"
DOI: 10.1007/s13555-020-00435-2
Abstract: Psoriasis Area and Severity Index (PASI) and Physician’s Global Assessment (PGA) are the most widely used outcome measures in clinical trials of biologics to treat psoriasis; however, these outcome measures vary in both their reliability… read more here.
Keywords: severity; pga; clearance; psoriasis ... See more keywords
Roflumilast Cream 0.3% in Patients with Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results from the DERMIS Phase III Trials
Sign Up to like & getrecommendations! Published in 2025 at "Dermatology and Therapy"
DOI: 10.1007/s13555-025-01562-4
Abstract: Roflumilast cream 0.3% contains a selective, highly potent phosphodiesterase 4 inhibitor approved to treat plaque psoriasis. The Psoriasis Area and Severity Index (PASI)-High Discrimination (PASI-HD) is more precise than PASI when psoriasis involves read more here.
Keywords: pasi pasi; roflumilast cream; pasi; plaque psoriasis ... See more keywords
Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-017-0274-0
Abstract: BackgroundPsoriasis is a common skin disease and moderate to severe psoriasis is associated with a dose-dependent risk for metabolic and cardiovascular morbidity. It has previously been speculated that women have less severe psoriasis, as men… read more here.
Keywords: area; severity; severe psoriasis; psoriasis ... See more keywords
Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2018.1457516
Abstract: Abstract Background: The clinical benefits of biologic therapies for moderate-to-severe psoriasis are well established, but wide variations exist in patient response. Objectives: To determine the number needed to treat (NNT) to achieve a 75% and… read more here.
Keywords: pasi; severe psoriasis; cost; moderate severe ... See more keywords
Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1746734
Abstract: Abstract Background: Relative Psoriasis Area and Severity Index (PASI) improvement, also called ‘PASI response’, is recommended in major guidelines for assessment of treatment response in psoriasis patients. However, under certain circumstances it has some limitations,… read more here.
Keywords: index; response; absolute pasi; treatment ... See more keywords
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2020.1747590
Abstract: Abstract Background It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment. Objectives To evaluate supplementing dichotomous efficacy with residual disease activity. Methods This post hoc analysis used… read more here.
Keywords: pasi; psoriasis; clinical trials; treatment ... See more keywords
Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15757
Abstract: NAVIGATE clinical trial demonstrated a higher rate of Psoriasis Assesment Severity Index (PASI)90 response in patients treated with guselkumab when compared to ustekinumab and an improved response in those who switched from ustekinumab to guselkumab… read more here.
Keywords: ustekinumab guselkumab; trial; pasi; dosage regime ... See more keywords
AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.2983
Abstract: Background Tildrakizumab (TIL), a high affinity, humanised, IgG1/κ monoclonal antibody for IL-23p19, recently demonstrated efficacy in patients with chronic plaque psoriasis in two, phase 3 clinical trials. Objectives To examine efficacy from baseline to week… read more here.
Keywords: week; pfizer; celgene; pasi pasi ... See more keywords
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Sign Up to like & getrecommendations! Published in 2024 at "Dermatologic Therapy"
DOI: 10.1155/2024/5528484
Abstract: Background. Current psoriasis treatment goals emphasize achieving complete or near‐complete skin clearance while preserving the quality of life, necessitating treatment modification for a suboptimal or inadequate response. Despite risankizumab’s demonstrated efficacy, evidence remains limited for… read more here.
Keywords: treatment; risankizumab; response; inadequate response ... See more keywords
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study
Sign Up to like & getrecommendations! Published in 2025 at "Psoriasis: Targets and Therapy"
DOI: 10.2147/ptt.s533005
Abstract: Background Clinical trials have demonstrated the efficacy of guselkumab in psoriasis, however, limited data are available from real-life studies evaluating the long-term effectiveness and drug survival (DS) of guselkumab. Objective This multicenter study assessed the… read more here.
Keywords: treatment; guselkumab; long term; study ... See more keywords